CARE Foundation Models
Foundation models for characterizing whole-slide images and detecting cancer across 40+ tissue types
Model · Api OnlyCompany source
Company profile
About Paige AI
Paige applies the power of foundation models to cancer care, delivering models that set new standards for size, scale and performance in pathology.
Company description Paige AI official website
Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Work at Paige AI?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- 40+ cancer types across multiple organs including lung, liver, ovary, cervix, endometrium, bladder, kidney, brain, head and neck, skin, bone, soft tissue, lymph node
- Breast cancer
- Colon cancer
- GI cancers (esophagus, stomach, small intestine, gall bladder, pancreas, large bowel, rectum)
- Prostate cancer
Who it serves
- Hospitals
- Life sciences organizations
- Pathology labs
- Pharma
- Research institutions
Deployment & integration
Api Only · Cloud Saas deployment with recorded integration context.
Recorded integration context: Multiple digital pathology platforms mentioned but not specifically named.
Geographic context
MarketsEurope · Global · United Kingdom · United States
Company sourceOfficial website
Company milestones
Platform expansion
Launch of Paige Alba multi-modal co-pilot, Paige GI Suite built on latest foundation model technology, expansion of PanCancer Suite to 40+ tissue types, OmniScreen predicting 1,600+ biomarkers from H&E alone
Partnerships
Recorded partners
- CROs
- Digital pathology platform providers
- Leading reference labs
- Microsoft (foundation model development)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
OmniScreen Characterization
AI module for comprehensive tissue characterization and biomarker analysis
Software · Cloud SaaSCompany source
OmniScreen Prescreening
Digital biomarker application predicting genomic alterations in 491 genes across multiple cancers
Software · Cloud SaaSCompany source
Paige Alba
Multi-modal AI co-pilot designed to revolutionize pathology workflows and unlock precision medicine
Software · Cloud SaaSCompany source
Paige Breast Suite
AI applications for identification and classification of breast cancer on H&E-stained whole-slide images
Software · Cloud SaaSCompany source
Paige GI Suite
AI-powered applications for detection and classification across the entire gastrointestinal tract
Software · Cloud SaaSCompany source
Paige PanCancer Suite
AI application identifying cancer across 40+ tissue types including rare cancers
Software · Cloud SaaSCompany source
Paige Platform
End-to-end digital pathology environment with integrated AI applications
Platform · Cloud SaaSCompany source
Paige Prostate Suite
AI-powered applications for prostate cancer detection and grading on H&E-stained whole-slide images
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
End-to-end multimodal pathology foundation model with clinical dialogue.Nature medicine · Jul 31, 2026
Comparing Gleason Pattern 4 Measurement Approaches on Prostate Biopsy Using Machine Learning: A Proof-of-Principle Study.medRxiv : the preprint server for health sciences · Apr 24, 2026
A deployment safety case for AI-assisted prostate cancer diagnosis.Computers in biology and medicine · Jun 1, 2025
A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms.Cancer research · Oct 15, 2024
Proteomic basis for pancreatic acinar cell carcinoma and pancreatoblastoma as similar yet distinct entities.NPJ precision oncology · Oct 3, 2024
Author Correction: BigNeuron: a resource to benchmark and predict performance of algorithms for automated tracing of neurons in light microscopy datasets.Nature methods · Oct 1, 2024
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Paige ProstateDEN200080 · De Novo · Sep 21, 2021
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
21.9% reduction in slide evaluation times
Paige Prostate Detect validation studies
65.5% reduction in time to diagnosis
Paige Prostate Detect
70% reduction in diagnostic error
Paige Prostate Detect
98% sensitivity for metastases detection
Paige Breast Lymph Node
55% reduction in lymph node slide reading time
Paige Breast Lymph Node
0.95 specimen-level AUC
PanCancer Detect across common and rare cancers
Leading pathology labs worldwide
AI-assisted prostate cancer detection and grading to improve diagnostic efficiency and accuracy
21.9% reduction in slide evaluation times, 65.5% reduction in time to diagnosis, 70% reduction in diagnostic error
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Paige AI
Recent articles published on Paige AI's official website.
Paige and NHS Wales Launch PanCancer Pilot to Triage Cases with AI at Betsi Cadwaladr University Health Board
Read on Paige AIBurjeel Holdings Partners with US-Based Paige to Deploy FDA-Approved AI in Cancer Diagnostics Across MENA
Read on Paige AIPaige Releases PRISM2: A Whole-Slide Foundation Model for Multimodal AI in Pathology and Cancer Care
Read on Paige AISectra’s fully managed AI offering extended to include pathology following new Amplifier partner agreement
Read on Paige AIPaige Releases PRISM2: A Whole-Slide Foundation Model for Multimodal AI in Pathology and Cancer Care
Read on Paige AI07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pathology & Laboratory Diagnostics
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.